

Regd. Office :
Zydus Tower,
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2666 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

August 17, 2017

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: Press Release

Dear Sir / Madam,

We enclose herewith a copy of press release dated August 17, 2017 titled “Zydus receives final approval from the USFDA for Telmisartan and Hydrochlorothiazide Tablets”.


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**


UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus receives final approval from the USFDA for Telmisartan and Hydrochlorothiazide Tablets

Ahmedabad, 17 August 2017

Zydus Cadila has received the final approval from the USFDA to market Telmisartan and Hydrochlorothiazide Tablets USP, in the strengths of 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg. Telmisartan and Hydrochlorothiazide Tablets are used to treat hypertension (high blood pressure). The drug will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The sales of Telmisartan and Hydrochlorothiazide Tablets is estimated at \$66.5 million.
Source: IMS Health, IMS National Sales Perspective Audit, MAT June 2017, extracted August 2017.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
